Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease
Phase of Trial: Phase IV
Latest Information Update: 29 Jun 2016
At a glance
- Drugs Donepezil (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Acronyms SAVE
- Sponsors Eisai Korea
- 20 May 2016 Status changed from active, no longer recruiting to completed.
- 04 Dec 2015 Planned End Date changed from 1 Sep 2015 to 1 Jan 2016, according to ClinicalTrials.gov record.
- 09 Sep 2015 Planned End Date changed from 1 Jul 2015 to 1 Sep 2015, as reported by ClinicalTrials.gov.